MPLT

Rating neutralAI Memo

MapLight Therapeutics

As of 2026-06-25/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-06-25 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Phase 2 ZEPHYR schizophrenia topline data due by mid-August 2026 • 2026-08-15

Expected move: -26%

Biggest risk

The bear case is that MPLT remains a low-coverage clinical-stage biotech with valuation concentrated in a narrow set of binary Phase 2 readouts; if either program disappoints, the lack of commercial diversification and limited external confirmation could pressure shares materially.

Invalidation

Break below $21 or thesis failure.

What would change my mind?

The bull case is that MPLT has two meaningful Phase 2 readouts arriving in the same mid-August 2026 window, with prior company updates showing enrollment completion in ZEPHYR and completion of the last patient visit in IRIS, while cash runway through 2027 lowers near-term financing overhang [#SEC-8K-2026-05-14].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-06-25

Base target

$28

p=45%

Bull target

$38

p=25%

Bear target

$21

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Runway supports execution into 2027 but leaves the stock primarily data-driven
The bull case is that MPLT has two meaningful Phase 2 readouts arriving in the same mid-August 2026 window, with prior company updates showing enrollment completion in ZEPHYR and completion of the last patient visit in IRIS, while cash runway through 2027 lowers near-term financing overhang [#SEC-8K-2026-05-14].
The stored analyst target summary shows a median of $39.5455 versus the $30.65 anchor price, but analyst target count is unavailable, so that apparent upside should be treated as low-confidence and secondary to the August 2026 data window.

BearKey bullets

Binary clinical-readout risk is the dominant risk, with both ZEPHYR and IRIS expected around mid-August 2026.
Cash runway is guided through 2027, but a weak readout could still reopen financing concerns for a pre-revenue biotech.
Low sell-side coverage and limited recent trusted-news context reduce confidence in external validation of the thesis.

WatchKey bullets

Phase 2 ZEPHYR schizophrenia topline data due by mid-August 2026

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $28 (p=45%)

Bull/Bear spread: +0% / -45%

Vs latest close: Bull +0% · Base -26% · Bear -45%

Scenario probabilities

Bull Target: $38 (p=25%)Base Target: $28 (p=45%)Bear Target: $21 (p=30%)

Commentary

Primary-source evidence quality is strong because the packet includes usable SEC-backed earnings/business-update excerpts, but the thesis is still a cautious monitoring view because recent trusted-news flow is sparse, social context is absent, and the deterministic prior is negative into a binary data window. Price reaction context and post-print analyst revisions are unavailable in the packet, so missing reaction data should not be treated as positive evidence.

As of 2026-06-25 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Runway supports execution into 2027 but leaves the stock primarily data-driven

Scenarios

Bull Target (Scenario probability)

$38 / p=25% prob

Base Target (Scenario probability)

$28 / p=45% prob

Bear Target (Scenario probability)

$21 / p=30% prob

Price $38 as of 2026-07-17

Nearest Scenario: Bull (∆ 0%)

Targets vs latest close: Bull +0% · Base -26% · Bear -45%

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-15
Phase 2 ZEPHYR schizophrenia topline data due by mid-August 2026
The main near-term value driver is ML-007C-MA Phase 2 ZEPHYR topline data after the company completed enrollment of 307 participants and guided to results by mid-August 2026 [#SEC-8K-2026-05-14].
Prob 70.00% • Move 24.00% • Priced-in 45.00%
EVENT2026-08-15
Phase 2 IRIS autism topline data due by mid-August 2026
ML-004 Phase 2 IRIS has completed last patient visit, with management guiding to topline results by mid-August 2026, creating a second binary readout close to the ZEPHYR window [#SEC-8K-2026-05-14].
Prob 68.00% • Move 18.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Runway supports execution into 2027 but leaves the stock primarily data-driven
2026-12-31
MapLight reported $395.2 million of cash, cash equivalents and investments at March 31, 2026 and said this should fund operations through 2027, which reduces immediate financing pressure but does not remove clinical-readout risk [#SEC-8K-2026-05-14].
Prob 75% • Move 8% • Priced-in 70%

Risks

Binary clinical-readout risk is the dominant risk, with both ZEPHYR and IRIS expected around mid-August 2026.
Cash runway is guided through 2027, but a weak readout could still reopen financing concerns for a pre-revenue biotech.
Low sell-side coverage and limited recent trusted-news context reduce confidence in external validation of the thesis.
Peer set is loose, so relative-valuation support is weaker than for more established biotech names.
The June 24, 2026 8-K is present in the packet but excerpt support is minimal, so it does not yet improve operating visibility beyond confirming a fresh filing exists [#8-K-2026-06-24].

Peers

Symbol	Summary
IMTX	Immatics is closer in market cap and clinical-stage profile than large-cap biopharma peers, but the indication set differs, so peer read-through is limited.
JBIO	Jade Biosciences is another small-cap biotech peer by size, though its program mix is not a tight operating comp; this reinforces that MPLT should be valued mainly on its own upcoming data.
AMGN	Amgen is sector-relevant but too large and commercially diversified to be a direct operating peer; it is useful only as a broad biotech sentiment reference.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-06-25

AI Stock Memo: MPLT - MapLight Therapeutics - RankAlpha